NEW YORK, NY / ACCESSWIRE / July 15, 2015 / Amarantus BioScience Holdings, Inc. (OTCQX: AMBS) today published a new blog post on The Chairman's Blog, guest written by Dr. Nicole Gibran, UW professor of surgery and director of the UW Medicine Regional Burn Center at Harborview Medical Center. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In her post, Dr. Gibran speaks about the importance of Engineered Skin Substitute (ESS) to the burn community and its potential to increase the survival rates in burn patients. As a longtime advocate for ESS, Dr. Gibran shares her excitement in hearing about Amarantus BioScience's involvement in ESS, writing, "When I heard this past week that Amarantus BioScience was going to revive this product opportunity, I was extremely excited that once again we would be able to get this important product to the burn population and allow burn providers another tool in their toolbox for helping these patients recover." Read the full blog post from Dr. Gibran on TheChairmansBlog.com (http://www.thechairmansblog.com/amarantus-bioscience/nicole-gibran/the-importance-of-ess-to-the-burn-community/).

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. AMBS' Therapeutics division has development rights to eltoprazine, a Phase 2b small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression, an exclusive worldwide license to intellectual property rights associated with Engineered Skin Substitute ("ESS"), an autologous full thickness skin replacement product in development for the treatment of severe burns and owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF-based products as treatments for brain and ophthalmic disorders. AMBS' Diagnostics division owns the rights to MSPrecise(R), a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test(R)) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro). AMBS also owns the discovery of neurotrophic factors (PhenoGuard(TM)) that led to MANF's discovery.

For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com

SOURCE: TheChairmansBlog.com

© 2024 Canjex Publishing Ltd. All rights reserved.